CA2825211A1 - Compositions de wnt et procedes d'utilisation de celles-ci - Google Patents

Compositions de wnt et procedes d'utilisation de celles-ci Download PDF

Info

Publication number
CA2825211A1
CA2825211A1 CA2825211A CA2825211A CA2825211A1 CA 2825211 A1 CA2825211 A1 CA 2825211A1 CA 2825211 A CA2825211 A CA 2825211A CA 2825211 A CA2825211 A CA 2825211A CA 2825211 A1 CA2825211 A1 CA 2825211A1
Authority
CA
Canada
Prior art keywords
wnt
mini
cell
polypeptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2825211A
Other languages
English (en)
Inventor
Kenan Christopher GARCIA
Aron LEVIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA2825211A1 publication Critical patent/CA2825211A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
CA2825211A 2011-01-28 2012-01-26 Compositions de wnt et procedes d'utilisation de celles-ci Abandoned CA2825211A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161462130P 2011-01-28 2011-01-28
US61/462,130 2011-01-28
PCT/US2012/022761 WO2012103360A2 (fr) 2011-01-28 2012-01-26 Compositions de wnt et procédés d'utilisation de celles-ci

Publications (1)

Publication Number Publication Date
CA2825211A1 true CA2825211A1 (fr) 2012-08-02

Family

ID=46581406

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2825211A Abandoned CA2825211A1 (fr) 2011-01-28 2012-01-26 Compositions de wnt et procedes d'utilisation de celles-ci

Country Status (10)

Country Link
US (1) US20140200179A1 (fr)
EP (1) EP2667889A4 (fr)
JP (1) JP2014506568A (fr)
KR (1) KR20140035337A (fr)
CN (1) CN103501799A (fr)
AU (1) AU2012211277A1 (fr)
BR (1) BR112013019280A2 (fr)
CA (1) CA2825211A1 (fr)
SG (1) SG192182A1 (fr)
WO (1) WO2012103360A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3065736A1 (fr) 2009-04-27 2010-11-04 Ottawa Hospital Research Institute Compositions et methodes permettant de moduler les cellules souches et leurs utilisations
SG11201400668SA (en) * 2011-09-16 2014-04-28 Fate Therapeutics Inc Wnt compositions and therapeutic uses of such compositions
ES2690305T3 (es) 2011-09-16 2018-11-20 Ottawa Hospital Research Institute Composiciones de Wnt7a y métodos de utilización de las mismas
WO2013149337A1 (fr) 2012-04-02 2013-10-10 Hydrogenics Corporation Procédé de démarrage de pile à combustible
WO2014194267A2 (fr) * 2013-05-30 2014-12-04 The Board Of Trustees Of The Leland Stanford Junior University Compositions de pharmacophores peptidiques wnt et leurs procédés d'utilisation
WO2015148923A1 (fr) * 2014-03-28 2015-10-01 Ottawa Hospital Research Institute Motilité induite par wnt et prise de greffe améliorée de cellules
WO2016040895A1 (fr) * 2014-09-12 2016-03-17 xxTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Molécules d'agonistes de la signalisation wnt
US10550364B2 (en) 2014-12-24 2020-02-04 Osaka University Method for producing Wnt protein and method for storing Wnt protein
WO2017132494A1 (fr) * 2016-01-28 2017-08-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions wnt et procédés de synthèse de celles-ci sans sérum
JP7216024B2 (ja) * 2017-05-31 2023-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍細胞におけるＷｎｔシグナル伝達と拮抗するポリペプチド
EP3728323A4 (fr) 2017-12-19 2022-01-26 Surrozen Operating, Inc. Anticorps anti-fzd et méthodes d'utilisation
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
WO2019126401A1 (fr) 2017-12-19 2019-06-27 Surrozen, Inc. Anticorps anti-lrp5/6 et leurs procédés d'utilisation
US12084684B2 (en) 2018-07-16 2024-09-10 The Board Of Trustees Of The Leland Stanford Junior University Frizzled specific Wnt agonists and antagonists
CN110305209B (zh) * 2019-07-09 2022-09-13 福建医科大学附属第一医院 用于治疗恶性肿瘤的多肽及其作为疫苗的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1622637A2 (fr) * 2003-05-15 2006-02-08 The University of Chicago Procedes et compositions de regeneration nerveuse
WO2006036175A2 (fr) * 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Proteines wnt et detection et traitement du cancer
EP2134352A4 (fr) * 2007-03-05 2011-05-25 Univ Leland Stanford Junior Compositions de wnt et procédés pour leur utilisation
WO2010014948A1 (fr) * 2008-08-01 2010-02-04 The University Of Utah Research Foundation Procédés de traitement utilisant des inhibiteurs de wnt
US20110319337A1 (en) * 2008-12-31 2011-12-29 Dawn Bravo Dominant Negative WNT2 Compositions and Methods of Use

Also Published As

Publication number Publication date
CN103501799A (zh) 2014-01-08
US20140200179A1 (en) 2014-07-17
WO2012103360A3 (fr) 2012-10-11
EP2667889A4 (fr) 2014-08-06
WO2012103360A2 (fr) 2012-08-02
BR112013019280A2 (pt) 2017-03-21
SG192182A1 (en) 2013-08-30
EP2667889A2 (fr) 2013-12-04
JP2014506568A (ja) 2014-03-17
AU2012211277A1 (en) 2013-08-29
KR20140035337A (ko) 2014-03-21

Similar Documents

Publication Publication Date Title
US20140200179A1 (en) Wnt compositions and methods of use thereof
AU2019203511B2 (en) CXCR4 binding molecules
RU2702553C2 (ru) Новое антитело против tie-2 человека
TW201809004A (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
CN104736185A (zh) 治疗Tau病变的方法
BR122020010972B1 (pt) polipeptídeo isolado e de fusão, sua composição farmacêutica e multímero
JPWO2016167306A1 (ja) 抗ヒトＮｏｔｃｈ４抗体
JP2022505152A (ja) 抗シヌクレイン抗体
TW202241519A (zh) 腫瘤特異性密連蛋白１８﹒２抗體藥物結合物
JP2012504946A (ja) 血小板第４因子変異体１（ｐｆ４ｖ１）に対する中和抗体およびそのフラグメント
JP6872756B2 (ja) 抗Ｍｙｌ９抗体
ES2831651T3 (es) Uso de anticuerpos y antagonistas dirigidos contra Lrg1 en un tratamiento
WO2014194267A2 (fr) Compositions de pharmacophores peptidiques wnt et leurs procédés d'utilisation
US20230357386A1 (en) Anti-epha4 antibody
WO2021190437A1 (fr) Anticorps contre areg et leur utilisation
US10421808B2 (en) Bak binding proteins
CA3214220A1 (fr) Nouvelles muteines de lipocaline specifiques au facteur de croissance des tissus conjonctifs (ctgf)

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170126